Skip to main content
. 2023 Oct 11;182(12):5259–5273. doi: 10.1007/s00431-023-05211-w

What is Known:

• GABHS disease spectrum ranges from superficial to invasive infections and toxin-mediated diseases.

• GABHS accounts for about 25% of sore throat in children and its management is a matter of debate.

What is New:

• Three strategies can be distinguished among current GLs: antibiotic therapy to prevent ARF, antibiotics only in complicated cases, and a tailored strategy according to the individual ARF risk.

• The impact of antibiotic treatment of GABHS pharyngitis on its sequelae still is the main point of divergence; further studies are needed to achieve a global shared strategy.